ZNF204P is a stemness-associated oncogenic long non-coding RNA in hepatocellular carcinoma

Ji-Hyun Hwang1, Jungwoo Lee1, Won-Young Choi1

  • 1Interdisciplinary Program of Integrated OMICS for Biomedical Science, The Graduate School, Yonsei University, Seoul 03722, Korea.

BMB Reports
|February 16, 2022
PubMed

Insights

This study identifies ZNF204P as a novel intracellular marker for liver cancer stem cells. Its knockdown inhibits tumor growth, suggesting a new therapeutic target for hepatocellular carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Hepatocellular carcinoma (HCC) presents a significant global health challenge, often diagnosed late and exhibiting resistance to chemotherapy.
  • The cancer stem cell (CSC) model explains tumor heterogeneity, recurrence, and chemoresistance, emphasizing the need for CSC identification and understanding their drivers.
  • Current extracellular CSC markers (e.g., CD133, CD90, EpCAM) require complex combinations for accurate identification.

Discussion:

  • Pseudogene-derived long non-coding RNAs (lncRNAs) are proposed as intracellular CSC markers due to their cancer-specific expression and regulatory roles in pluripotency and self-renewal.
  • Microarray data analysis identified ZNF204P, a pseudogene-derived lncRNA, as a stemness-associated factor in liver cancer.
  • Experimental validation showed that ZNF204P knockdown significantly impairs HCC cell proliferation, migration, and invasion.

Key Insights:

  • ZNF204P functions as an intracellular marker for liver cancer stem cells.
  • ZNF204P knockdown demonstrates potent anti-tumor effects on HCC cells.
  • The lncRNA ZNF204P is proposed to promote tumorigenesis via the miRNA-145-5p/OCT4, SOX2 axis.

Outlook:

  • ZNF204P represents a promising therapeutic target for overcoming chemoresistance and reducing recurrence in HCC.
  • Further research into the regulatory network of ZNF204P could reveal additional therapeutic strategies for liver cancer.
  • Understanding the role of pseudogene-derived lncRNAs in cancer stemness may lead to novel diagnostic and therapeutic approaches.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.9K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.0K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
9.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K